NeuroXNet: Creating A Novel Deep Learning Architecture that Diagnoses Neurological Disorders, Finds New Blood Biomarkers, and Assesses Surgical, Drugs, and Radiation Treatment Plans Using Medical Imaging and Genomic Data

Vaibhav Mishra

doi:10.1101/2021.12.13.21267728

Abstract

Neurodegenerative diseases and cancerous brain tumors cause millions of patients worldwide to be fatally ill and face cognitive impairment each year. Current diagnosis and treatment of these neurological conditions take many days, are sometimes inaccurate, and use invasive approaches that could endanger the patient’s life. Thus, this study’s purpose is the creation of a novel deep learning model called NeuroXNet, which uses MRI images and genomic data to diagnose both neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, and Mild Cognitive Impairment as well as cancerous brain tumors, including glioma, meningioma, and pituitary tumors. Moreover, the model helps find novel blood biomarkers of differentially expressed genes to aid in diagnosing the six neurological conditions. Furthermore, the model uses patient genomic data to give additional recommendations for treatment plans that include various treatment approaches, including surgical, radiation, and drugs for higher patient survival for each class of the disease. The NeuroXNet model achieves a training accuracy of 99.70%, a validation accuracy of 100%, and a test accuracy of 94.71% in multi-class classification of the six diseases and normal patients. Thus, NeuroXNet reduces the chances of misdiagnosis, helps give the best treatment options, and does so in a time/cost-efficient manner. Moreover, NeuroXNet efficiently diagnoses diseases and recommends treatment plans based on patient data using relatively few parameters causing it to be more cost and time-efficient in providing non-invasive approaches to diagnosis and treatment for neurological disorders than current procedures.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study involves only openly available human data, which can be obtained from: ADNI (http://adni.loni.usc.edu/), PPMI (https://www.ppmi-info.org/), Kaggle (https://www.kaggle.com/sartajbhuvaji/brain-tumor-classification-mri/metadata), and Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74385, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31095, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4488, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63063, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6613, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4226).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

http://adni.loni.usc.edu/

https://www.ppmi-info.org/

https://www.kaggle.com/sartajbhuvaji/brain-tumor-classification-mri/metadata

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74385

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31095

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4488

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63063

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6613

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4226

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.